BBT 031
Alternative Names: BBT-031; Long-acting PEGylated somatropin - Bolder BioTechnology; PEG-GH - Bolder BioTechnology; PEG-growth hormone - Bolder BioTechnology; Pegylated-growth hormone - Bolder BioTechnology; Pegylated-somatropin - Bolder BioTechnologyLatest Information Update: 19 Jun 2023
Price :
$50 *
At a glance
- Originator Bolder BioTechnology
- Class Growth hormones; Hormonal replacements; Polyethylene glycols
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Somatotropin deficiency
- Discontinued Lipodystrophy; Short stature
Most Recent Events
- 19 Jun 2023 BBT 031 is still in preclinical development for Somatotropin-deficiency in USA (Parenteral) (Bolder Biotechnology pipeline, June 2023)
- 28 May 2022 No recent reports of development identified for preclinical development in Somatotropin-deficiency in USA (Parenteral, Injection)
- 20 May 2020 BBT 031 is available for licensing as of 20 May 2020. http://www.bolderbio.com/